Publication: Comparison of plasmapheresis with medical apheresis in terms of efficacy and cost in the acute treatment of hypertriglyceridemia in children with
dc.contributor.author | Erdöl, Şahin | |
dc.contributor.author | Bilgin, Hüseyin | |
dc.contributor.author | Sağlam, Halil | |
dc.contributor.buuauthor | ERDÖL, ŞAHİN | |
dc.contributor.buuauthor | BİLGİN, HÜSEYİN | |
dc.contributor.buuauthor | SAĞLAM, HALİL | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Pediatri Anabilim Dalı/Metabolizma Bilim Dalı | |
dc.contributor.orcid | 0000-0002-6598-8262 | |
dc.contributor.researcherid | GLN-8241-2022 | |
dc.contributor.researcherid | JMQ-9930-2023 | |
dc.contributor.researcherid | HSF-7083-2023 | |
dc.date.accessioned | 2024-06-27T07:33:49Z | |
dc.date.available | 2024-06-27T07:33:49Z | |
dc.date.issued | 2021-11-01 | |
dc.description.abstract | Objectives: We aimed to compare plasmapheresis and medical apheresis as lipid-lowering therapies in children with familial lipoprotein lipase (LPL) deficiency. Methods: The data of 13 patients who were followed up after a diagnosis of LPL deficiency were retrospectively analyzed. Plasma triglyceride, cholesterol, amylase, and lipase values and complications were recorded before and after each patient underwent plasmapheresis or medical apheresis. Results: The mean follow-up period of the patients was 99.64 +/- 52.92 months in the medical apheresis group and 118 +/- 16.97 months in the plasmapheresis group. While the mean triglyceride level before plasmapheresis was 1,875.38 +/- 547.46 mg/dL, it was 617 +/- 228.28 mg/dL after plasmapheresis. While the mean triglyceride level before medical apheresis was 1,756.86 +/- 749.27 mg/dL, it was found to be 623.03 +/- 51.36 mg/dL after medical apheresis. Triglyceride levels were decreased by 59.62% with medical apheresis and 65.57% with plasmapheresis. The cost of treatment for medical apheresis was found to be lower compared to plasmapheresis 296.93 +/- 29.94 Turkish lira (USD 43.34 +/- 4.01) vs. 3,845.42 +/- 156.17 Turkish lira (USD 561.37 +/- 20.93; p<0.001). Conclusions: Although there is no standardized strategy for the acute treatment of hypertriglyceridemia due to LPL deficiency, medical apheresis is a safe and effective treatment with a low risk of side effects. Unlike plasmapheresis, medical apheresis can be performed in any center, which is another important advantage of the procedure. A greater catabolism. diabetes, tions gene the titis, xhantoms acute zil, familial and these there treatment. ting | |
dc.identifier.doi | 10.1515/jpem-2021-0260 | |
dc.identifier.eissn | 2191-0251 | |
dc.identifier.endpage | 1424 | |
dc.identifier.issn | 0334-018X | |
dc.identifier.issue | 11 | |
dc.identifier.startpage | 1419 | |
dc.identifier.uri | https://doi.org/10.1515/jpem-2021-0260 | |
dc.identifier.uri | https://www.degruyter.com/document/doi/10.1515/jpem-2021-0260/html | |
dc.identifier.uri | https://hdl.handle.net/11452/42488 | |
dc.identifier.volume | 34 | |
dc.identifier.wos | 000717373400008 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Walter | |
dc.relation.journal | Journal Of Pediatric Endocrinology & Metabolism | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Lipoprotein-lipase | |
dc.subject | Pancreatitis | |
dc.subject | Patient | |
dc.subject | Insulin | |
dc.subject | Deficiency | |
dc.subject | Mutations | |
dc.subject | Therapy | |
dc.subject | Hypertriglyceridemia | |
dc.subject | Insulin | |
dc.subject | Lipoproteinlipase deficiency | |
dc.subject | Medical apheresis | |
dc.subject | Plasmapheresis | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Endocrinology & metabolism | |
dc.subject | Pediatrics | |
dc.title | Comparison of plasmapheresis with medical apheresis in terms of efficacy and cost in the acute treatment of hypertriglyceridemia in children with | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 20f0e0ab-299b-4991-a5bc-4c6021265d5e | |
relation.isAuthorOfPublication | 2b20b93d-cba7-4607-8ff3-2122b9a800be | |
relation.isAuthorOfPublication | 0ea2245f-bcba-4a84-b68a-fdbc43ac8913 | |
relation.isAuthorOfPublication.latestForDiscovery | 20f0e0ab-299b-4991-a5bc-4c6021265d5e |